Quick Pitch: Elevation Oncology (ELEV)

Potential Liquidation or Sale — 60% Upside (at $0.28/share)

It’s not a new name in the land of busted biopharmas, but after dropping 22% last week for no obvious reason, it’s starting to look interesting.

The setup is fairly standard. In March, Elevation Oncology discontinued its lead program after disappointing Phase 1 results, cut 70% of its workforce, and launched a strategic review. With a market cap of $16.5m, ELEV now trades at roughly 50% discount to its guided mid-year cash of $30m-$35m.

The stock price dropped sharply last week following Q1 earnings. To be honest, it’s not clear why, as there was nothing new or concerning in the update. Cash burn was normal as well. Maybe the market was expecting more concrete steps or details on the strategic review.

There was, however, one particularly interesting and positive detail that the market may have overlooked: management decided to provide cash guidance for June 30:

Elevation Oncology estimates that it will have cash, cash equivalents and marketable securities in a range of approximately $30 million to $35 million as of June 30, 2025

Making this kind of a cash projection is very unusual in similar situations. It almost never happens. Management teams of a busted cash shells have no real reason to burden themselves with this extra effort—unless they are trying to send a message. One way this guidance could be interpreted as is a flashing neon sign for potential buyers and investors.

I’ve only seen it happen twice before, and both cases turned out quite well. Let me know in the comments below if you know any other precedents. The first was ALLK (covered on SSI here), which gave a mid-year cash estimate during a strategic review announcement in Jan’25. In two months, ALLK was acquired by Kevin Tang. The second was THRD, which also provided mid-year cash guidance with its strategic review announcement in Feb’25, and then announced a liquidation two months later. Given that most busted biopharmas drift into questionable reverse mergers, both outcomes were also unusually favorable for shareholders.

Maybe I’m reading too much into it and trying to find a pattern where there isn’t one. However, the idea that this kind of a proactive management team might go and do a shareholder-friendly thing doesn’t seem that crazy.

Either way, this setup includes a bunch of other positive aspects as well:

• ELEV probably has the cleanest balance sheet out of all busted biopharmas. There’s no debt, no operating leases, just $30m+ in guided cash, $0.5m in payables, and $3.7m in accrued expenses. That’s basically it.
• The decision to fully halt its lead program looks shareholder friendly. It was actually a mix of three studies—one monotherapy and two combo trials. The monotherapy readout was expected in Q2’25, while the combo arms in Q4’25/Q1’26. But after seeing weak monotherapy data, management shut everything down in March.
• A 70% headcount reduction was announced immediately, and included the Chief Medical Officer. Only 10 employees remain.
• Shortly after, the company repaid its $32m loan in full. This seems like another sign of things winding down. However, one could also argue that the company simply had no reason to keep holding that debt as, after trial failure, the second credit tranche ($20m) probably became unavailable.
• In last week’s Q1 update, management confirmed the strategic review.
• Kevin Tang and BML Investment Partners each own 10% of ELEV. Tang has been an investor for a few years. However, BML disclosed its stake the same day the trial failure was announced and the stock dropped by 40%. So, it most likely bought in at around current share price levels.
• Last month, BML sent a blunt letter to ELEV’s management. That’s also something you don’t often see in busted biopharmas. The activist supported the cash-preservation steps and the launch of a strategic review but made it clear it wouldn’t back any plans that didn’t come with a “large return of cash to shareholders.” It wouldn’t be surprising if Tang shares the same view. The stock jumped to $0.36/share (vs. $0.28 now) and held there for several weeks.
• No poison pill or other defensive maneuvers have been announced by the company.
• ELEV’s chairman owns a 5% stake. He is also a managing partner at Aisling Capital, a life sciences investment firm. He’s clearly not a “science-for-science’s-sake” guy. He should know what a discount to cash means and what his incentives are. His annual comp is $170k. Prompt realization of ELEV’s net cash would net him many times that amount.
• The CEO also has a background in healthcare investment banking, including executive director of Global Healthcare at UBS Investment bank.
• Director Timothy P. Clarkson has a particularly relevant pedigree. He was CEO of THRX, which was acquired by Tang in 2023 under very similar circumstances. He was also Chief Scientific Officer at ARIAD (sold to Takeda for $5.2bn) and later became CEO of IDRx after it was bought by pharma giant GSK for $1.2bn.
• Other directors are also well-credentialed. Alan Sandler was CMO of Mirati (acquired by BMY for $5.8bn), Julie Cherington also served on Mirati’s board, and Darcy Mootz was CEO of Amunix (after acquisition by Sanofi for $1bn).

Taken together, these aspects suggest the strategic review could lead to a favorable outcome for shareholders at the current price. I also think things could move fairly quickly from here. Management chose to guide mid-year cash, which is just around the corner, when they easily could’ve pointed to Q3 or year-end, if they expected a longer process.

 

What is the expected upside?

I’m including my calculations of liquidation value below, which suggest the potential upside of 30%-60%. In a buyout scenario, results should be similar.

The key difference between the two scenarios shown above is working capital liabilities. It’s quite possible they don’t need to be deducted from mid-year cash. Here’s why.

After accounting for debt repayment and restructuring costs to be incurred in Q2, the guided mid-year cash implies an additional ~$13m of cash burn in this quarter. That’s roughly in line with Q1’s $12.7m burn, and also above last year’s run-rate. That doesn’t quite add up—how can expenses stay flat in Q2 after discontinuing the main trial and cutting 70% of the workforce in March?

One likely explanation is that the cash guidance already includes the settlement of the remaining working capital liabilities. If that’s the case, the upside here could be ~60%. If not, and those liabilities still need to be deducted, the upside would be closer to 30%.

These estimates assume a liquidation or a deal soon after mid-year, somewhere around late July. $1m-$2m contingency reserve feels plenty for such a tiny cash-shell with a super clean balance sheet.

The main reason this situation exists is likely because, alongside the strategic review, the company has continued developing its only remaining program, which is still in the preclinical stage. That’s clearly not ideal and adds some uncertainty around management’s intentions.

Still, it’s not necessarily a red flag. Consider these two very similar situations (both were already mentioned above):

• THRX: suspended its lead Phase 1/2 program, laid off 72% of its workforce, and launched a strategic review in 2023. At the same time, it continued to develop two preclinical programs. In Nov’23, Kevin Tang made a buyout offer at a 9% discount to net cash. Management didn’t respond immediately, but a definitive merger agreement was signed a few weeks later.
• THRD: at the time of the strategic review announcement in Feb’25, it also didn’t suspend its only remaining Phase 1 program. In fact, THRD stated that the program “supports advancement” into Phase 2 and that management would begin preparations. Nonetheless, the company ultimately decided to liquidate.

Rather than focusing on the standalone fact that ELEV is still funding early-stage development, it makes more sense to look at the actual steps that the company has been taking so far. Most of those point in a positive direction—from the launch of the strategic review and large-scale layoffs, to the decision not to adopt a poison pill despite two large activists on the register, and the addition of mid-year cash guidance in the Q1 update.

 

A few additional details

• The main trial was focused on gastric and gastresophageal junction cancers. It was discontinued because objective response rate (ORR) turned out to be only 22%.
• The remaining preclinical program EO-1022 focuses on HER3-expressing solid tumors. I have no idea if it’s worth anything, and given how early it is (IND expected next year), I’m not holding out hope.
• ELEV has a large number of options and warrants outstanding, but all are deeply out of the money. There’s been some speculation on another public blog that, in a merger or sale scenario, the warrants might have to be cashed out at a Black-Scholes valuation. But the financing proxy makes it clear that’s not the case (emphasis mine):

In the event of a fundamental transaction, as described in the purchase warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets […] the holders of the purchase warrants will be entitled to receive upon exercise of the purchase warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the purchase warrants immediately prior to such fundamental transaction without regard to any limitations on exercise contained in the purchase warrants.